Climb Bio Will Present Kidney Data in Denver
The biotech firm will showcase findings on two investigational treatments at the upcoming Kidney Week 2026.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you trust that new medical breakthroughs from biotechnology firms will genuinely improve patient health outcomes?
Climb Bio will present clinical data for its treatments CLYM116 and budoprutug during the American Society of Nephrology Kidney Week 2026 in Denver, Colorado. The presentations are scheduled to take place between October 21 and October 25, 2026.
Why it matters
These presentations allow the company to highlight clinical advancements across its development portfolio for immune-mediated kidney diseases. The data will provide insight into the potential efficacy of its pipeline products for patients suffering from chronic conditions.
The data covers three immune-mediated kidney diseases, involving CLYM116, an anti-APRIL monoclonal antibody, and budoprutug, a low-fucosylated anti-CD19 monoclonal antibody. Development continues on a subcutaneous formulation for budoprutug.
The players
Climb Bio
Climb Bio is a clinical-stage biotechnology company that focuses on the development of novel therapies for immune-mediated diseases.
American Society of Nephrology
The American Society of Nephrology is a professional organization dedicated to supporting the study and treatment of kidney diseases.
The details
Climb Bio has scheduled several oral presentations and poster sessions throughout the conference to detail its research progress. The company is developing budoprutug for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with the former having both Orphan Drug and Fast Track FDA designations.
Timeline
October 21-25, 2026: ASN Kidney Week 2026 conference dates
October 22, 2026: CLYM116 poster presentation
October 23, 2026: CLYM116 and budoprutug poster presentations
October 24, 2026: Budoprutug oral presentation
The Tech Race
The American Society of Nephrology Kidney Week conference serves as the primary industry stage for unveiling breakthroughs in renal therapeutics. Climbing Bio's presence here follows a broader trend of mid-stage biotech firms using high-visibility academic platforms to validate their clinical pipelines.
For patients and medical providers, these presentations offer an early look at potential new treatment options for complex autoimmune conditions. The data provides critical information regarding the future availability of therapies that may eventually address currently unmet medical needs.
The takeaway
Clinical presentations at large industry conferences are a vital step in the regulatory and validation pathway for new biopharmaceutical drugs. Observers should look for the forthcoming data releases to understand the potential impact these treatments may have on current standards of care.
Further reading
Learn more about the latest industry developments in our Biotech section.
Live Poll
Do you trust that new medical breakthroughs from biotechnology firms will genuinely improve patient health outcomes?
